Samsung Bioepis and Organon expand commercialization of Pyzchiva
Summary
Samsung Bioepis and Organon expanded their agreement so Organon can commercialize Pyzchiva in Canada. Pyzchiva is a biosimilar to Johnson & Johnson’s Stelara. The news also notes that Organon is being acquired by Sun Pharmaceutical Industries in an all-cash deal. For vendors and partners, the expansion suggests continued commercialization, regulatory, and market-access work around the product and its regional rollout.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected